SQUARE PHARMA KENYA Launches Bactoken® (Mupirocin 2% USP) Ointment (19 November, 2025)
SQUARE PHARMA KENYA proudly announced the official launch of Bactoken® (Mupirocin 2% USP) Ointment, a topical antibiotic for effective treatment of bacterial skin infections. The launch event was held at the prestigious Sarova Panafric Hotel, in presence of an impressive gathering of 160 HCPs of Kenya.
During the event, medical experts and senior representatives from SQUARE discussed the therapeutic benefits, safety profile, and clinical relevance of Backtoken® (Mupirocin 2% USP) Ointment in daily practice. The launch program strengthened collaboration with Kenyan healthcare professionals and demonstrated the company’s ongoing dedication to delivering world-class pharmaceutical solutions.
During the event, medical experts and senior representatives from SQUARE discussed the therapeutic benefits, safety profile, and clinical relevance of Backtoken® (Mupirocin 2% USP) Ointment in daily practice. The launch program strengthened collaboration with Kenyan healthcare professionals and demonstrated the company’s ongoing dedication to delivering world-class pharmaceutical solutions.
SPKEL receives EAC GMP Approval (15 October, 2025)
We are pleased to announce that our manufacturing facility in Kenya — SQUARE PHARMACEUTICALS KENYA EPZ LTD — has received GMP (Good Manufacturing Practice) approval from the East African Medicines Regulatory Harmonization (EAC-MRH) Authority on 15 October, 2025.
This certification under the EAC GMP Harmonization framework ensures that our operations meet the unified quality, safety, and efficacy standards recognized across the eight EAC member states — Burundi, the Democratic Republic of Congo, Kenya, Rwanda, Somalia, South Sudan, Tanzania, and Uganda.
This milestone reaffirms SQUARE’s unwavering commitment to global quality standards, regulatory compliance, and sustainable healthcare solutions — strengthening our capability to serve partners and patients across East Africa and beyond.
This certification under the EAC GMP Harmonization framework ensures that our operations meet the unified quality, safety, and efficacy standards recognized across the eight EAC member states — Burundi, the Democratic Republic of Congo, Kenya, Rwanda, Somalia, South Sudan, Tanzania, and Uganda.
This milestone reaffirms SQUARE’s unwavering commitment to global quality standards, regulatory compliance, and sustainable healthcare solutions — strengthening our capability to serve partners and patients across East Africa and beyond.
SPKEL marks historic milestone with its First Export (19 September, 2024)
SQUARE PHARMACEUTICALS KENYA EPZ LTD (SPKEL) has achieved a historic milestone on 19 September, 2024 with a flag-off ceremony – celebrating the 1st ever export of its pharmaceuticals from its Athi River, EPZ manufacturing plant in Kenya.
This achievement marks the company’s continued commitment to delivering innovative, high-quality healthcare solutions on the global scale.
This achievement marks the company’s continued commitment to delivering innovative, high-quality healthcare solutions on the global scale.
SPKEL launches its 1st Products in Kenya (23 February, 2023)
SQUARE PHARMACEUTICALS KENYA EPZ LTD (SPKEL) launches its 1st products in Kenya on 23 February, 2023. The products are Melcam® 7.5 & Melcam® 15 Tablet (Meloxicam).
As a local manufacturer in Kenya, SPKEL plays a strategic role in improving national medicine security and regional supply resilience. By producing essential generics and finished dosage forms within Kenya, SPKEL shortens supply chains, lowers import dependency, accelerates time-to-market for priority therapies, and creates skilled local employment in Kenya.
As a local manufacturer in Kenya, SPKEL plays a strategic role in improving national medicine security and regional supply resilience. By producing essential generics and finished dosage forms within Kenya, SPKEL shortens supply chains, lowers import dependency, accelerates time-to-market for priority therapies, and creates skilled local employment in Kenya.
Groundbreaking of SPKEL (8 January, 2018)
On January 8, 2018 (Monday), Square Pharmaceuticals Kenya EPZ Ltd started the construction work of its state-of-the-art pharmaceutical manufacturing plant through a grand Groundbreaking Ceremony in Nairobi, Kenya.
The Managing Director of Square Pharmaceuticals - Mr. Tapan Chowdhury joined with other dignitaries from the Ministry of Industry, Trade and Cooperatives, the Kenya EPZ Authority, World Bank, IFC, Standard Chartered Bank to celebrate the groundbreaking ceremony of “Square Pharmaceuticals Kenya EPZ Ltd”.
The Managing Director of Square Pharmaceuticals - Mr. Tapan Chowdhury joined with other dignitaries from the Ministry of Industry, Trade and Cooperatives, the Kenya EPZ Authority, World Bank, IFC, Standard Chartered Bank to celebrate the groundbreaking ceremony of “Square Pharmaceuticals Kenya EPZ Ltd”.
